This publication supports the scientific groundwork for the CREAATE study but provides no new clinical data or regulatory milestone. The near-term catalyst remains the Phase 3 CREAATE readout and the HAE NDA outcome. Monitor for those events — this filing alone does not change the stock's trajectory.
Price Chart
Executive Summary
Pharvaris announced publication of the first in-depth qualitative study in AAE-C1INH in Frontiers in Immunology, validating PRO measures and directly informing endpoint selection for the ongoing Phase 3 CREAATE study of deucrictibant. There are currently no approved therapies for this ultra-rare, serious disease. This is a scientific milestone that supports the regulatory path but does not change the stock's near-term fundamentals.
Key Facts
- First in-depth qualitative study in AAE-C1INH published in peer-reviewed journal Frontiers in Immunology.
- Study validates PGI-C, PGI-S, and PGA as meaningful PRO instruments for this indication.
- Findings directly informed design and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) of deucrictibant.
- No approved therapies exist for prevention or treatment of AAE-C1INH attacks — all patients currently rely on off-label therapies.
- Pharvaris is a late-stage biopharma developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema.
Financial Impact
No financial data disclosed; the announcement pertains to a disease framework publication, not financial results or deal terms.
Risk Factors
- CREAATE study may fail to replicate prior deucrictibant efficacy/safety in AAE-C1INH.
- Regulatory path for AAE-C1INH remains unclear; FDA may require additional trials beyond CREAATE.
- Deucrictibant NDA for HAE on-demand treatment has uncertain outcome and timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access